Paul McKenzie - CSL Chief Officer
| CMXHF Stock | USD 171.40 5.38 3.04% |
Executive
Dr. Paul F. McKenzie is appointed as Chief Operating Officer of the Company., effective 3 June 2019. He has served in a range of progressive operational leadership roles in the biopharma and biotech industries since 1992. Most recently, he was Executive Vice President of Pharmaceutical Operations Technology at Biogen where he was accountable for asset management, technical development, global manufacturing, supply chain operations, CMC regulatory, quality and engineering. Dr. McKenzie also held leadership roles in research development, science technology and operations with Johnson Johnson, BristolMyers Squibb and Merck earlier in his career. He earned his BS degree in Chemical Engineering from the University of Pennsylvania and was awarded his Ph.D. in Chemical Engineering from Carnegie Mellon University. Dr. McKenzie is an accomplished author and thought leader on operational excellence in the biotech industry. since 2019.
| Age | 57 |
| Tenure | 6 years |
| Phone | 61 3 9389 1911 |
| Web | https://www.csl.com.au |
CSL Management Efficiency
The company has return on total asset (ROA) of 0.0798 % which means that it generated a profit of $0.0798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1964 %, meaning that it generated $0.1964 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joan MBA | Verve Therapeutics | 56 | |
| MPH MD | ProKidney Corp | N/A | |
| Joanne Choi | Legend Biotech Corp | N/A | |
| Sravan Emany | Beam Therapeutics | 47 | |
| Dr MBA | Zai Lab | 43 | |
| Tolga MBA | Alnylam Pharmaceuticals | 52 | |
| Sheila MD | Ventyx Biosciences | 55 | |
| Richard Williams | ProKidney Corp | N/A | |
| Scott Holmes | Ascendis Pharma AS | N/A | |
| Amy MD | Beam Therapeutics | 61 | |
| Michael Carulli | Pmv Pharmaceuticals | 51 | |
| Troy Lister | Verve Therapeutics | N/A | |
| Cristi Barnett | Editas Medicine | N/A | |
| Stina MD | Ascendis Pharma AS | 51 | |
| Pharm MPH | ProKidney Corp | N/A | |
| Baisong MD | Editas Medicine | 61 | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Susan OConnor | Beam Therapeutics | 60 | |
| David MD | Intellia Therapeutics | 70 | |
| Christine Chiou | Zai Lab | N/A | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0798 |
CSL Limited Leadership Team
Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul McKenzie, Chief Officer | ||
| BCom BComm, Chief Officer | ||
| Wilfried Freudenberg, Department Production | ||
| Christina Hickie, Sr Communications | ||
| BS BS, Exec Counsel | ||
| MS BA, Ex Officer | ||
| Karen Etchberger, Executive VP of Quality and Bus. Services | ||
| Paul BA, CEO MD | ||
| Jemimah Brennan, Head Pacific | ||
| Mark Dehring, Director of Investor Relations, IR Contact Officer |
CSL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0798 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 96.65 B | |||
| Shares Outstanding | 482.22 M | |||
| Shares Owned By Insiders | 0.41 % | |||
| Shares Owned By Institutions | 35.50 % | |||
| Price To Earning | 33.44 X | |||
| Price To Book | 6.65 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in CSL Pink Sheet
CSL financial ratios help investors to determine whether CSL Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSL with respect to the benefits of owning CSL security.